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ABSTRACT 
Background: Familial colorectal cancer type X (FCCX) is a subtype of mismatchrepair (MMR)-proficient 
colorectal cancerin whichthe patients are clinicallyat risk for Lynch syndrome (LS), a common hereditary 
cancer predisposing syndrome.In this study, we describeda new clinicopathological feature of the condition in 
central Iran. 
Subjects and Methods: We designed a descriptive, retrospective study to screenat-riskcolorectal cancer 
(CRC) patients,usingAmsterdam II criteria and Molecular analysis in Isfahan (central Iran) throughout 2000-
2013 period. 
Results: 219 early-onset (≤ 50 years) CRC patients of 1659 were selected for the evaluation. Amsterdam II 
criteria were positive in 45 families; of whom 31 were finally analyzed by molecular testing.   
MMR deficiency was detected in 7/31 probands (22.6%) as affected to LS, so 24 families (77.4%) were 
identified as FCCX. The mean age of the probands at diagnosis among FCCX families was 45.3 years (range 
24-69) versus 38.0 years (range 31-50) in LS families.The frequency of CRC among FCCX and LS families was 
calculated 27.9% and 67.5%, respectively. Also, the most frequent extracolonic cancer among both FCCX and 
LS families was stomach by 25.5% and 30.8%, respectively. Tumor site was proximal to the splenic flexure in 
20.8% and 57.1% of index CRC patients in FCCX and LS families, respectively. 
Conclusion: Given the relative high frequency of FCCXand its different phenotype among Iranian populations, 
we need to set up more advanced molecular studies for exploration of unknown molecular pathways leading to 
tumorigenesis in this class of CRC patients.  
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INTRODUCTION 
   Colorectal cancer (CRC), the second cause of 
cancer-related mortality throughout the world1,3, 
presents hereditary pattern in at least 20% of the 
cases of which about 5% are related to inherited 
mutations in known cancer-predisposing genes and 
the rest has likely linked to unknown genetic 
changes4-6. 
Hereditary nonpolyposis colorectal cancer (HNPCC) 
is used to describe a familial cluster of CRCwithnon-
polyposis phenotype. At first, the Amsterdam 
criteria (AC) were introducedto screen CRC patients 
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at risk for HNPCCaccordingtoa positive family 
history with at least three affected family members 
in two or more generations, and one being a first-
degree relative of the other two and at least one 
individual diagnosed before 50 years of age7. The 
AC1 refers to families with at least three colorectal 
cancers, while in AC2Lynch-associatedextracolonic 
cancers containingcancers of endometrium, upper 
urinary tract, small bowel, stomach, liver, brain, 
breast, and skin were also included8,9.  
The HNPCC families are clinically heterogeneous of 
which about 4% are linked to Lynch syndrome 
(LS),which may be negative for AC, <1% are 
attributed to a Lynch-like syndrome, and 2–4% are 
defined as familial colorectal cancer type X (FCC-
X)10,11. LS is identified by germline mutations in at 
least one of the mismatch-repair (MMR) genes 
including: MLH1, MSH2,MSH6, and PMS2, however, 
just about one-third of the LS families fulfill the AC 
criteria12-15.Although, Lynch-like syndrome 
(LLS)clinically demonstrates AC and tumors with 
functional MMR gene defects according to 
immunohistochemical staining and/or microsatellite 
instability (MSI) testing, no MMR gene mutations 
are found to justify the disease16,18. FCC-X families 
are AC positive families with MMR-proficient 
tumors and no MMR gene mutations12,19,20. 
According to recent studies, it seems there is a high 
frequency of FCC among Iranian populations2,9, 21-
23.Meanwhile,no studies have been so far reported 
to describe clinicopathologic feature of FCC-Xamong 
our populations.Accordingly, we try to report a new 
description of FCC-X families in Central Iran. 
 
SUBJECTS AND METHODS 
   We undertook a descriptive retrospective study to 
screenFCC patients at risk for LSin Isfahan, Central 
Province of Iran. Of 1659 CRC patients registered in 
Poursina Hakim Research Center (PHRC), a referral 
gastrointestinal cancer center in Isfahan Province, in 
the 14-year period (2000-2013),at first all patients 
aged ≤ 50 years were included in our study as the 
early-onset patients. Then, all CRC patients with 
Amsterdam II criteria and their families were 
invitedfor genetic counseling through which the 
participants were interviewed about cancer-related 
familyhistory at-least up to three generations. 
Amsterdam II criteria for primary clinical screeningin our 
study included: having at least 3 affected members 
with one of the HNPCC-associated cancers (CRC, 
other GI cancers, endometrial, renal, breast 
(according to some resources), brain, skin, and 
pelvic cancers) in at least two successive 
generations, and being one of these three members 
a first-degree relative of the other two and at least 
one diagnosed before the age of 50 years. 
The drawn pedigrees were reconfirmed by at-least 
two other members of every family. Besides, the 
cancer pathologic reportsrelated to all affected 
family memberswere possibly requestedto confirm 
the diagnosis, if available. Then, all resected tumors 
related to the index CRC patients were analyzed 
molecularly by both MSI testing and 
Immunohistochemistry (IHC) to detect probable 
MMR deficiency. 
To detect MSI, a commercial pentaplex panel from 
Promega (MSI Analysis System, Version 1.2) 
including five mononucleotide markers (BAT-
25,BAT-26, MON0-27,NR-21, and NR-24) was used, 
and two pentanucleotide markers (PentaC and 
PentaD) were used as indicators to detect specimen 
mix-ups. We considered tumorsasMSI-High (MSI-H) 
if atleast two of five 
quasimononucleotidemarkersshowed instability and 
MSI-Low (MSI-L) if only one marker was unstable. 
For IHC, we used a formalin-fixed paraffin-
embedded (FFPE)tissue block for each case, 
including both tumoral and adjacent healthy 
mucosa. After providing at least a proper section for 
each protein, we treated the slides with primary 
antibodies related to MMR proteins according to 
IHC guideline specific for each immunologic 
product. The properties of the antibodies were as 
following: MSH2 (Leica Biosystems: Novocastra, UK, 
Lyophilized, Product Code (PC): NCL-MSH2) at 1/80 
dilution, MLH1 (Leica Biosystems: Novocastra, UK, 
Liquid, PC: NCL-L-MLH1) at 1/100 dilution, MSH6 
(Leica Biosystems: Novocastra, UK, Liquid, PC: NCL-
L-MSH6) at 1/100 dilution, and PMS2 (Leica 
Biosystems: Novocastra, UK, Liquid, PC: NCL-L-
PMS2) at 1/100 dilution.Then, the slides were 
incubated with Post Primary Block reagent and DAB 
working solution for some minutes, respectively. If 
the MMR protein has been expressed, the nuclear 
staining will be present. MMR deficiency leads to 
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absent nuclear staining in tumor section compared 
to normal adjacent tissue. 
Data were analysed using SPSS statistics software 
(Ver.19). 
 
Ethical approval 
Ethical approval was received from the Medical 
Ethics Committee of Shahrekord University of 
Medical Sciences (Research project Number: 003). 
The research was carried out according to principles 
set out in the Declaration of Helsinki 1964 and all 
subsequent revisions.Informed consent was 
obtained, and the privacy and confidentiality were 
observed throughout the study. 
 
RESULTS 
   We finally identifiedthat 413/1659 (24.9%)CRC 
patients registered in PHRCthroughout 2000-2013 
period were affected by early-onset (age ≤ 50 years 
at diagnosis) CRC. Family history was positive in 72 / 
219 patients responding probands (32.9%) and 
among whom we found finally 53 families (24.2%) 
with at least three members affected by any type of 
Lynch-associated cancer according to Amsterdam II 
criteria. We classified them as “Familial Colorectal 
Cancer” (FCC) families.  Using Amsterdam II criteria, 
45/53FCC families were clinically identified as 
HNPCC families and were considered candidates for 
molecular testing.The 14 probands were excluded 
due to lack of their tumor tissues or being unwilling 
to incorporate. 
After both MSI testing and IHC-MMRs, 7 index CRC 
patients were identified as MMR-deficient group 
(22.6%), while no MMR deficiency was finally 
detected among the rest of 24 probands and they 
were classified as “FCC-X” patients (77.4%). 
Mean age at diagnosis inMMR-deficient probands 
was 38.0 years (range 31-50) versus 45.3 years 
(range 24-50) (P value < 0.05)among FCC-X 
probands. 
Among MMR-deficient probands, altogether, 57.2% 
of tumors were located in right colon (including 
cecum, ascending colon, and transverse 
colon),while among FCC-X probands 20.8% of 
tumors were located in right colon.  
History of cancer was found in 186 members within 
31 HNPCC families. Of whom, 140 cancer patients 
were related to 24 FCC-X families (5.8 patients per 
family) and 46 cancer patients were belonged to 7 
MMR-deficient families (6.6 patients per family) 
(Figures 1, 2). 
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Age at diagnosis of cancer was averagely 51.7 and 
51.0 among FCC-X families and MMR-deficient 
families, respectively (P-value = 0.817). 
Colorectal, stomach, and hematopoietic system 
with 67.4, 8.7, and 6.5 percent, respectively were 
most frequent cancers among MMR-deficient 
families, while among FCC-X families, colorectal, 
stomach and lung with 39.3, 10.0, and 8.6 percent, 
respectively, were most frequent cancers (Table 1). 
 
Table 1: Cancer sites among Iranian families with familial colorectal 
cancers in both FCC-X and MMR deficient subsets 
Cancer site FCC-X families MMR deficient 
families 
Sum 
Frequency Percent Frequency Percent 
Colorectal 55 39.3 31 67.4 86 
Stomach 14 10.0 4 8.7 18 
Lung 12 8.6 2 4.3 14 
Breast 11 7.9 1 2.2 12 
Brain 9 6.4 0 0.0 9 
Hepatobiliary tract 7 5.0 2 4.3 9 
Intestine 6 4.3 0 0.0 6 
Prostate 4 2.9 2 4.3 6 
Uterus 4 2.9 1 2.2 5 
Skin 3 2.1 0 0.0 3 
Hematopoietic system 3 2.1 3 6.5 6 
Bladder 3 2.1 0 0.0 3 
Thyroid 2 1.4 0 0.0 2 
Testis 2 1.4 0 0.0 2 
Bone 2 1.4 0 0.0 2 
Kidney 1 0.7 0 0.0 1 
Pancreas 1 0.7 0 0.0 1 
Nasopharynx 1 0.7 0 0.0 1 
Total 140 100 46 100 186 
FCC-X: Familial colorectal cancer type X; MMR: Mismatch-repair 
 
Pathologically, 8/24 of FCC-X probands (33.3%) 
were diagnosed at early stages (I or II pathologic 
TNM stage). In MMR-deficient probands, however, 
1/7 (14.3%) cases were diagnosed at early stages 
Moreover, mortality rate among FCC-X probands 
and MMR-deficient probands was 11/24(45.8%) and 
1/7 (14.3%), respectively in our study. 
 
DISCUSSION 
This paper is the first description of FCC-X among 
Iranian patients. Given the absence of any 
systematic program for screening and 
earlydetection of at-risk Iranian families, we tried to 
set up a new pilot study to explore 
clinicohistopathologic and epidemiologic features of 
familial colorectal cancer in central Iran. 
Accordingly, we applied AC-II to screen CRC patients 
atrisk for Lynch syndrome.  
More than 74% of our Amsterdam positive 
probands were MMR-proficient, determining a 
likely high prevalence of FCC-X among our 
population. According to different studies, 
particularly among western countries, averagely 21-
73% of CRC patients with clinical AC-I/AC-II criteria 
represent finally FCC-X12,24-26. Apparently, the 
frequency of FCC-X among Iranian CRC patients is 
more than western countries. So, more molecular 
evaluations are necessary to explore genetic causes 
of this common subtype of CRC among our 
population. 
 
Distinct Clinicopathologic Phenotype 
Our FCC-X probands were diagnosed averagely 
more than 7 years later than MMR-deficient 
probands. It is similar to other studies around the 
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world, so according to a review article, it was 
calculated 57.3 years in FCC-X versus 49.7 in Lynch 
syndrome27-30. Moreover, a majority of FCC-X CRC 
tumors were found in left colon (79.2% vs. 42.8% in 
MMR-deficient tumors). It has been also presented 
in many similar studies among other populations 
according which 70% of FCC-X CRC have been found 
in left side colon12,30-32. 
Although there was no meaningful difference 
between FCC-X and MMR-deficient families in case 
of mean age at diagnosis and the average number 
of cancer patients (rather than probands), 
extracolonic cancers in FCC-X families included 
more spectrum than MMR-deficient ones. So, 
altogether 18 organs were affected in cancer 
patients among FCC-X families versus 8 organs in 
MMR-deficient families. This finding is against the 
results obtained from similar studies among other 
non-Iranian populations, so according to some of 
the findings, the risk of extracolonic cancers is 
increased in Lynch syndrome compared to FCC-X 
families33-35. 
Although a more proportion of FCC-X probands in 
comparison to MMR-deficient ones was identified 
in early pathologic stage (33.3% vs. 14.3%), 
mortality rate of FCC-X probands was calculated 
higher than MMR-deficient ones (45.8% vs.14.3%). 
It could be due to a relative better survival in MMR- 
deficient CRC patients in comparison to FCC-X CRC 
patients, an issue for which there is much evidence 
in worldwide studies12,34-37. 
 
Distinct clinical phenotype of FCC-X tumors in 
comparison to MMR-deficient ones is suggestive of 
a different molecular basis for this common subtype 
of CRC about which more evaluations are necessary. 
It also proposes a different protocol for screening 
and early detection of cancer among FCC-X families. 
Therefore, given the high frequency of FCC-X among 
Iranian population, setting up a native screening 
program according to different properties of all CRC 
subtypes must be considered.  
 
CONCLUSION 
   Although there is not enough data about clinical, 
molecular, and histopathological features of familial 
colorectal cancer among Iranian populations, 
apparently FCC-X subset of this group of cancers is 
more frequent in our population. Distinct clinical 
andhistopathological phenotype of FCC-X is 
suggestive of new molecular mechanisms. It also 
underscores the necessity of revision in guidelines 
for screening and early-detection of cancer among 
FCC-X families. 
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